
Support truly
independent journalism
Shares in Novo Nordisk, the company behind obesity drug Wegovy were down 1.1% on Tuesday after data analysis showing a rival treatment leads to faster and greater weight loss.

Shares in Novo Nordisk, the company behind obesity drug Wegovy were down 1.1% on Tuesday after data analysis showing a rival treatment leads to faster and greater weight loss.